drugset / Trial / NCT02963116

A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet

NCT02963116

Phase 1 Completed 12 enrolled AstraZeneca
RandomizedCrossoverOpen-labelOther

Summary

This study is a randomized, open-label, 5-period, 5-treatment, single-dose, single-center, crossover study to estimate the effect of AZD5718 on the pharmacokinetics (PK) of rosuvastatin, and to assess the relative bioavailability of AZD5718 oral suspension vs AZD5718 immediate release (IR) Tablet Formulation and the Food Effect of AZD5718 in Healthy Volunteers. The study will be performed at a single study center.

Timeline

Start
2016-12-20
Primary completion
2017-03-01
Completion
2017-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atuliflapon Small molecule 200 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral